198 related articles for article (PubMed ID: 38622359)
21. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
22. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
23. OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine.
López-Cortés A; Paz-Y-Miño C; Guerrero S; Cabrera-Andrade A; Barigye SJ; Munteanu CR; González-Díaz H; Pazos A; Pérez-Castillo Y; Tejera E
Sci Rep; 2020 Mar; 10(1):5285. PubMed ID: 32210335
[TBL] [Abstract][Full Text] [Related]
24. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
25. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
Kyrochristos ID; Ziogas DE; Roukos DH
Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574
[TBL] [Abstract][Full Text] [Related]
26. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
28. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
29. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
30. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract][Full Text] [Related]
31. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
Naorem LD; Muthaiyan M; Venkatesan A
J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
[TBL] [Abstract][Full Text] [Related]
32. Toward individualized breast cancer therapy: translating biological concepts to the bedside.
Hortobagyi GN
Oncologist; 2012; 17(4):577-84. PubMed ID: 22474069
[TBL] [Abstract][Full Text] [Related]
33. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Kangaspeska S; Hultsch S; Jaiswal A; Edgren H; Mpindi JP; Eldfors S; Brück O; Aittokallio T; Kallioniemi O
BMC Cancer; 2016 Jul; 16():378. PubMed ID: 27378269
[TBL] [Abstract][Full Text] [Related]
34. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
37. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells.
Cun J; Yang Q
Biomed Pharmacother; 2018 Nov; 107():117-128. PubMed ID: 30086458
[TBL] [Abstract][Full Text] [Related]
39. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
[TBL] [Abstract][Full Text] [Related]
40. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
